Cadient Group Board Of Directors Announces Christopher French As Interim CEO; CEO Resigns

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Jan. 28, 2004--Cadient Group's Board of Directors today announced the resignation of President and Chief Executive Officer Robert Weissman. Cadient's Board of Directors selected fellow board member Christopher J. French to serve as interim chief executive officer. The board will conduct a nationwide search to fill the position on a permanent basis.

"I know I speak for the entire board when I offer my heartfelt thanks and best wishes to Bob Weissman for the contributions he has made to Cadient over the past several years. He played a significant role in the company's success, particularly, in the transition from Qwest Solutions to the Cadient Group," said Brian Tierney, chairman of Cadient Group's Board of Directors. "We respect Bob's wishes and know he will be successful in his next endeavor. Fortunately for Cadient, its clients and employees, Bob leaves behind a gifted team in Jim Burke, Craig Douglass, Tiffany Mura and Ashesh Shah who are as dedicated as ever to achieving great things for Cadient's clients."

"I don't think I could imagine a better person than Chris French to serve as interim CEO. Chris has a deep background in the pharmaceutical industry from his experience at Dendrite International," said Tierney. "Chris has a great strategic view of where the online pharmaceutical market is going and under his leadership, Cadient will not lose a step."

Prior to joining Cadient Group, French served as senior vice president of global solutions marketing at Dendrite International, Inc. French was also a member of Dendrite's operating committee, which advised the company's chief executive officer regarding the company's present business and future direction. Dendrite International, Inc. is a global provider of sales and marketing information, software and services solutions to pharmaceutical and other life sciences companies. As a member of Dendrite International's senior management team, French increased revenues from $45 million to $400 million from 1996 to 2003, a greater than 700% increase.

"I am excited to serve as Cadient Group's interim CEO," said Christopher French. "Cadient is a cutting-edge company, comprised of a team of smart, dedicated employees. Serving as chairperson of the corporate development committee at Cadient, I am especially familiar with the company's present operations as well as its strategic direction of the future."

Brian Tierney, who became chairman of Cadient Group's Board of Directors several months ago, is a nationally recognized advertising executive. Tierney's former company, Tierney Communications is now a wholly-owned subsidiary of the Interpublic Group of Companies. Tierney currently serves as the Founding Partner of T2 Group, a public relations, issue management and crisis communications firm in Philadelphia, PA.

Cadient's Board of Directors did not offer a timetable for the nationwide search to replace French as chief executive officer.

About Cadient Group

A world-class online pharmaceutical marketing agency, Cadient develops and deploys precise online marketing programs. These programs address the behavioral patterns of consumers and healthcare professionals and move them to try, purchase, prescribe and remain loyal to specific brands. Cadient's primary mission is to deliver demonstrative results for pharmaceutical companies seeking to activate consumer behavior, launch, build and sustain Rx and OTC brands. Cadient works with many of the world's leading pharmaceutical companies including AstraZeneca, Procter & Gamble, GlaxoSmithKline, and Johnson & Johnson. For more information, please visit www.cadient.com.

Contacts

Cadient Group by T2 Group Joseph Conti, 215-231-3702 215-880-4513 (cell)